Pulse Biosciences Announces Completion Of 164-Patient Enrollment In Pivotal Atrial Fibrillation Study Of nPulse Catheter, Three Months Ahead Of Schedule
Share
Why It Matters
Pulse Biosciences finished recruiting patients for their heart-rhythm study early. Early completion can hint the company is moving forward smoothly.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.